I guess I have been a professional analyst and investor for the last twenty-six years, but obviously as a buy side and not a sell side operator. As I may have said before, I learnt early on that the more I could ignore brokers and do my own research, the better I would do. And that still remains my thought today as I still think, a bit like the academic world, the biggest risk is that you end up knowing more and more about less and less. And that brings us to today’s Q3 update from Reckitt Benckiser (RKT).

Last October I observed that Reckitt Benckiser (RKT) ‘without working hard offers the scope for a £60-70 share price plus picking up a dividend’. In short a holding in the ‘home to the world’s best loved and trusted hygiene, health and nutrition brands’ group theoretically for FY22 is probably over ten times more interesting than government bonds or money in the bank. How many times a month do you – or someone in your household – use Finish, Dettol, Air Wick, Nurofen, Vanish, Harpic, Calgon or Durex products? My guess is more than once. So what about the shares today post the group’s full year numbers publication?

Pest control and hygiene company, Rentokil Initial (RTO), wasn’t looking particularly strong even prior to the arrival of Covid-19 and was trading at a very racey valuation, in my opinion.

Having, since August AIM admission, looked at “a number” of potential bolt-on acquisitions to broaden its product offering, REACT Group  (REAT) has announced “the expansion of its service offerings into Licensed Asbestos Removal and Occupational Hygiene Services”.